Pharmacokinetics and pharmacodynamics of the enantiomers of gallopamil

Journal of Pharmacology and Experimental Therapeutics

Volumn 281, Issue 3, 1997, Pages 1102-1112

  Gross, A S ^a,c   Mikus, G ^a   Ratge, D ^b   Wisser, H ^b   Eichelbaum, M ^a  

^a DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^b ROBERT BOSCH HOSPITAL   (Germany)

^c ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ANTAGONIST; GALLOPAMIL;

ARTICLE; CALCIUM ANTAGONISM; DRUG CLEARANCE; ENANTIOMER; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROTEIN BINDING; STEREOCHEMISTRY; URINALYSIS;

ADULT; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; GALLOPAMIL; HEART; HUMANS; MALE;

EID: 0030922114     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. BAYER, R., KAUFMANN, R. AND MANNHOLD, R.: Inotropic and electrophysiological actions of verapamil and D600 in mammalian myocardium. II. Pattern of inotropic effects of the optical isomers. Naunyn-Schmiedeberg's Arch. Pharmacol. 290: 69-80, 1975.
2. BROGDEN, R. N. AND BENFIELD, P.: Gallopamil. Drugs 47: 93-115, 1994.
3. BROWNE, T. R.: Stable isotopes in clinical pharmacokinetic investigations. Clin. Pharmacokinet. 18: 423-433, 1990.
4. CHELLINGSWOHTH, M. C. AND KENDALL, M. J.: Effects of nifedipine, verapamil and diltiazem on renal function. Br. J. Clin. Pharmacol. 25: 599-602, 1988.
5. DE SERVI, S., FERRARIO, M., GHIO, S., MUSSINI, A., ANGOLI, L., BRAMUCCI, E., BARTOLI, A., POMA, E., RONDANELLI, R. AND SPECCHIA, G.: Coronary haemodynamic effects of short term intravenous administration of gallopamil in patients with stable exertional angina. Br. Heart J. 57: 226-231, 1987.
6. ECHIZEN, H., BRECHT, T., NIEDERGESASS, S., VOGELGESANG, B. AND EICHELBAUM, M.: The effect of dextro-, levo, and racemic verapamil on atrioventricular conduction in humans. Am. Heart J. 109: 210-217 1985a.
7. ECHIZEN, H., VOGELGESANG, B. AND EICHELBAUM, M.: Effects of d,l-verapamil on atrioventricular conduction in relation to its stereoselective first-pass metabolism. Clin. Pharmacol. Ther. 36: 221-227, 1985b.
8. EICHELBAUM, M.: Pharmacokinetics and metabolism of gallopamil. Z. Kardiol. 78: suppl. 5, 20-24, 1989.
9. EICHELBAUM, M. AND GROSS, A. S.: Debrisoquine/sparteine genetic polymorphism: Clinical aspects. Pharmacol. Ther. 46: 377-394, 1990.
10. EICHELBAUM, M. AND GROSS, A. S.: Stereochemical aspects of drug action and disposition. Adv. Drug Res. 28: 1-64, 1996.
11. EICHELBAUM, M., MIKUS, G. AND VOGELGESANG, B.: Pharmacokinetics of (+)-, (-)-and (±)-verapamil after intravenous administration. Br. J. Clin. Pharmacol. 17: 453-458, 1984.
12. EICHELBAUM, M., VON UNRUH, G. E. AND SOMOGYI, A.: Application of stable labelled drugs in clinical pharmacokinetic investigations. Clin. Pharmacokinet. 7: 490-507, 1982.
13. FARIA, D. B., GONCALVES, F. R. AND MAROKO, P. R.: Three-dimensional analysis of infarct size reduction after administration of gallopamil in dogs. Arzneim. Forsch. 40: 19-23, 1990.
14. FISCHER, C., SCHÖNBERGER, F., MÜCK, W., HEUCK, K. AND EICHELBAUM, M.: Simultaneous assessment of the intravenous and oral disposition of the enantiomers of racemic nimodipine by chiral stationary-phase high-performance liquid chromatography and gas chromatography/mass spectroscopy combined with stable isotope technique. J. Pharm. Sci. 82: 244-250, 1993.
15. GROSS, A. S., BORSTEL, B. AND EICHELBACM, M.: Determination of gallopamil in serum by gas chromatography-mass spectrometry. J. Chromatogr. (Biomed. Appl.) 525: 183-192, 1990.
16. HOLFORD, N. H. G. AND SHEINER, L. B.: Understanding the dose-effect relationship: Clinical application of pharmacokinetic-pharmacodynamic models. Clin. Pharmacokinet. 6: 429-453, 1981.
17. HOPF, R., DREWS, H. AND KALTENBACH, M.: Die antianginöse Wirkung von Gallopamil im Vergleich mit einem anderen Calcium antagonisten und Placebo. Z. Kardiol. 73: 578-585, 1984.
18. KHURMI, N. S., O'HARA, M. J., BOWLES, M. J., SUBRAMANIAN, V. B. AND RAFTERY, E. B.: Randomized double-blind comparison of gallopamil and propranolol in stable angina pectoris. Am. J. Cardiol. 53: 684-688, 1984.
19. KROEMER, H. K., ECHIZEN, H., HEIDEMANN, H. AND EICHELBAUM, M.: Predictability of the in vivo metabolism of verapamil from in vitro data: Contribution of individual metabolic pathways and stereoselective aspects. J. Pharmacoi Exp. Ther. 260: 1052-1057, 1992.
20. LIMA, J. J., MACKICHAN, J. J., LIBERTIN, N. AND SABINO, J.: Influence of volume shifts on drug binding during equilibrium dialysis: Correction and attenuation. J. Pharmacokinet. Biopharm. 11: 483-498, 1983.
21. MCTAVISH, D. AND SORKIN, E. M. VERAPAMIL: An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in hypertension. Drugs 38: 19-76, 1989.
22. MARKUS, H. S., CHONG, E. M. F AND WILCOX, R. G.: Gallopamil slow release: A double blind study of twice daily versus once daily treatment in chronic stable angina. Eur. J. Clin. Pharmacol. 42: 271-274, 1992.
23. MAST, V., FISCHER, C., MIKUS, G. AND EICHELBAUM, M.: Use of pseudorecemic nitrendipine to elucidate the metabolic steps responsible for stereoselective disposition of nitrendipine enantiomers. Br. J. Clin. Pharmacol. 33: 51-59, 1992.
24. MIKUS, G., EICHELBAUM, M., FISCHER, C., GUMULKA, S., KLOTZ, U. AND KROEMER, H. K.: Interaction of verapamil and cimetidine: Stereochemical aspects of drug metabolism, drug disposition and drug action. J. Pharmacol. Exp. Ther. 253: 1042-1048, 1990.
25. MÜLLER, B. AND WILSMANN, K.: Effects of the optical isomer of D600 on cardiovascular parameters and on arrhythmias caused by aconitine and coronary artery ligation in anesthetized rats. J. Cardiovasc. Pharmacol. 4: 615-621, 1982.
26. MUTLIB, A. E. AND NELSON, W. L.: Pathways of gallopamil metabolism: Regiochemistry and enantioselectivity of the N-dealkylation processes. Drug Metab. Dispos. 18: 331-337, 1990a.
27. MUTLIB, A. E. AND NELSON, W. L.: Pathways of gallopamil metabolism: Regiochemistry and enantioselectivity of the O-demethylation processes. Drug Metab. Dispos. 18: 309-314, 1990b.
28. NAWRATH, H. AND RASCHACK, M.: Effects of (-)-desmethoxyverapamil on heart and vascular smooth muscle. J. Pharmacol. Exp. Ther. 242: 1090-1097, 1987.
29. NICHOLS, A. I. AND PECK, C. C.: LSNLR: A General Weighted Least Squares Nonlinear Regression Program. U.S.P.H.S. version 1.0, technical report no. 5.0, Division of Clinical Pharmacology and Medicine, Uniformed Services University for the Health Sciences. 1981.
30. RETTIG, G., SEN, S., SCHIEFFER, H. AND BETTE, L.: Acute and long-term effects of gallopamil (D600) in chronic stable angina pectoris: A randomized placebo-controlled double-blind trial. Z. Kardiol. 72: 746-754, 1983.
31. ROWLAND, M. AND TOZER, T. N.: Clinical Pharmacokinetics: Concepts and Applications. Lea & Febiger, Philadelphia, 1989.
32. RUTLEDGE, D. R. AND PIEPER, J. A.: Gallopamil binding to human serum proteins. Eur. J. Clin. Pharmacol. 33: 375-380, 1987.
33. RUTLEDGE, D. R. AND SZLACKY, M.: The effect of pH on gallopamil protein binding. Pharmaceut. Res. 5: 619-620, 1988.
34. SCRUTINIO, D., LAGIOIA, R., ACCETTURA, D., PREZIUSI, N., MASTROPASQUA, F. AND RIZZON, P.: Dose-response effectiveness of gallopamil for the treatment of chronic stable effort angina pectoris: comparison with propranolol. Curr. Ther. Res. 37: 830-842, 1985.
35. SCHWARZ, J. B., VEROTTA, D. AND SHEINER, L. B.: Pharmacodynamic modeling of verapamil effects under steady-state and non-steady-state conditions. J. Pharmacol. Exp. Ther. 251: 1032-1038, 1989.
36. SIEGEL, S.: Nonparametric Statistics for the Behavioural Sciences. McGraw-HiIl Ltd., Tokyo, 1956.
37. SOMOGYI, A., EICHELBAUM M. AND GUGLER, R.: Prediction of bioavailability for drugs with a high first-pass effect using oral clearance data. Eur. J. Clin. Pharmacol. 22: 85-90, 1982.
38. STIEREN, B., BÜHLER, V., HEGE, H. G., HOLLMANN, M., NEUSS, H., SCHLEPPER, M. AND WEYMANN, J.: Pharmakokinetik und Metabolismus von Gallopamil. Gallopamil, Pharmakologisches und klinisches Wirkungsprofil eines Kalziumantagonisten, ed. by M. Kaltenbach and R. Hopf, pp. 90-96, Springer-Verlag, Berlin, 1983.
39. VAN AMSTERDAM, F. T. M., PUNT, N. C., HAAS, M. AND ZAAGSMA, J.: Stereoisomers of calcium antagonists distinguish a myocardial and vascular mode of protection against ischemic injury. J. Cardiovasc. Pharmacol. 15: 198-204, 1990.
40. VOGELGESANG, B., ECHIZEN, H., SCHMIDT, E. AND EICHELBAUM, M.: Stereoselective first-pass metabolism of highly cleared drugs: Studies of the bioavailability of L- and D-verapamil examined with a stable isotope technique. Br. J. Clin. Pharmacol. 18: 733-740, 1984.
41. WEYMANN, J., BÜHLER, V., HEGE, H. G., MÜLLER-PELTZER, H., SCHENK, G., STIEREN, B. AND HOLLMANN, M.: Metabolism of the calcium antagonist gallopamil in man. Arzneim. Forsch. 39: 605-607, 1989.
42. WILKINSON, G. R., GUENGERICH, F. P. AND BRANCH, R. A.: Genetic polymorphism of S-mephenytoin hydroxylation. Pharmacol. Ther. 43: 53-76, 1989.